AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
80_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
2_CD
Share_NN
of_PIN
turnover_NN
and_CC
operating_VBG
profits_NN
of_PIN
joint_JJ
venture_NN
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Share_NN
of_PIN
joint_JJ
venture_NN
turnover_NN
227 208 191_CD
There_EX
was_VBD
no_SYNE
share_NN
of_PIN
operating_VBG
profits_NN
of_PIN
the_DT
joint_JJ
venture_NN
attributable_JJ
to_PIN
the_DT
Group_NN
._.
On_PIN
1_CD
September_NN
2004_CD
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
its_PIT
interest_NN
in_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
of_PIN
Advanta_NN
BV_NN
,_,
its_PIT
only_DWNT
major_JJ
joint_JJ
venture_NN
._.
The_DT
profit_NN
on_PIN
disposal_NN
is_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
Note_NN
3_CD
._.
3_CD
Exceptional_JJ
items_NN
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [PASS]
Accrual_NN
related_VBN [WZPAST]
to_PIN
Zoladex_NN
investigation_NOMZ
350_CD
Exceptional_JJ
items_NN
included_VBN [WZPAST]
in_PIN
operating_GER
profit_NN
350_CD
Profit_NN
on_PIN
sale_NN
of_PIN
interest_NN
in_PIN
joint_JJ
venture_NN
219_CD
Total_JJ
exceptional_JJ
items_NN
before_IN
taxation_NOMZ
219_CD
350_CD
Net_JJ
taxation_NOMZ
credit_NN
67_CD
Total_JJ
exceptional_JJ
items_NN
after_IN
taxation_NOMZ
286_CD
350_CD
The_DT
profit_NN
on_PIN
sale_NN
of_PIN
interest_NN
in_PIN
joint_JJ
venture_NN
relates_VPRT
to_PIN
the_DT
disposal_NN
of_PIN
the_DT
Groups_NN
interest_NN
in_PIN
the_DT
ordinary_JJ
share_NN
capital_NN
of_PIN
Advanta_NN
BV_NN
._.
There_EX
is_VPRT
a_DT
tax_NN
credit_NN
of_PIN
$_$
9m_CD
arising_VBG
on_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
the_DT
disposal_NN
._.
As_IN
set_VBN
out_PIN
in_PIN
more_EMPH
detail_NN
in_PIN
Note_NN
5_CD
,_,
the_DT
Company_NN
announced_VBD [PUBV]
on_PIN
20_CD
June_NN
2003_CD
a_DT
settlement_NOMZ
of_PIN
the_DT
US_FPP1
Department_NOMZ
of_PIN
Justice_NN
investigation_NOMZ
into_PIN
the_DT
US_FPP1
sales_NN
and_PHC
marketing_GER
practices_NN
for_PIN
Zoladex_NN
goserelin_NN
acetate_NN
implant_VPRT
._.
Negotiations_NOMZ
towards_PIN
this_DEMO
settlement_NOMZ
were_VBD [SPAU] [PASS]
sufficiently_RB
advanced_VBN
to_TO
recognize_VB [PRIV]
an_DT
exceptional_JJ
charge_NN
of_PIN
$_$
350m_CD
at_PIN
31_CD
December_NN
2002_CD
._.
An_DT
agreement_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
reached_VBN
with_PIN
the_DT
US_FPP1
tax_NN
authorities_NOMZ
that_DEMP
$_$
170m_CD
of_PIN
the_DT
settlement_NOMZ
is_VPRT [BEMA]
deductible_PRED
for_PIN
tax_NN
purposes_NN
._.
Consequently_CONJ
an_DT
exceptional_JJ
tax_NN
credit_NN
of_PIN
$_$
58m_CD
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
in_PIN
2004_CD
._.
These_DEMO
items_NN
are_VPRT [PASS]
regarded_VBN
as_IN
exceptional_JJ
due_JJ
to_PIN
their_TPP3
unusual_JJ
and_PHC
non-recurring_JJ
nature_NN
._.
There_EX
were_VBD
no_SYNE
exceptional_JJ
items_NN
in_PIN
2003_CD
._.
4_CD
Net_JJ
interest_NN
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Interest_NN
receivable_NN
and_CC
similar_JJ
income_NN
from_PIN
investments_NOMZ
Securities_NOMZ
10_CD
21_CD
21_CD
Short_JJ
term_NN
deposits_NN
81_CD
75_CD
90_CD
Gain_NN
on_PIN
disposal_NN
of_PIN
interest_NN
rate_NN
swap_NN
30_CD
Exchange_NN
gains_NN
15_CD
19_CD
6_CD
136 115 117_CD
Interest_NN
payable_JJ
and_PHC
similar_JJ
charges_NN
Loan_NN
interest_NN
30_CD
7_CD
10_CD
Interest_NN
on_PIN
short_JJ
term_NN
borrowings_GER
and_CC
other_JJ
financing_GER
costs_NN
16_CD
16_CD
51_CD
Discount_NN
on_PIN
liability_NOMZ
3_CD
10_CD
Exchange_NN
losses_NN
16_CD
46_CD
26_CD
87_CD
Net_JJ
interest_NN
receivable_NN
90_CD
89_CD
30_CD
